Exact Sciences (NASDAQ:EXAS) Acquisition by Abbott Laboratories: A Strategic Move in Cancer Diagnostics

Core Insights - Exact Sciences has been downgraded from a Buy to a Neutral rating by Guggenheim amid its acquisition by Abbott Laboratories [1][6] - Abbott Laboratories has agreed to acquire Exact Sciences for $105 per share, valuing the company at approximately $21 billion, with an enterprise value of about $23 billion including net debt [2][6] - Exact Sciences is projected to exceed $3 billion in revenue this year, with high-teens organic growth anticipated [3][6] Company Developments - The acquisition by Abbott is expected to close in the second quarter of 2026 and will enhance Abbott's revenue growth and gross margin immediately [2][3][6] - Exact Sciences is recognized for its innovative cancer diagnostics solutions, including Cologuard and Cancerguard, solidifying its strong market position [1][5] Market Performance - The stock price of Exact Sciences is currently at $101.29, reflecting a 17.53% increase, marking its highest price in the past year [4] - The market capitalization of Exact Sciences is approximately $19.19 billion, with a historical low of $38.81 over the past year [4]